RT Journal Article
SR Electronic
T1 Population homogeneity for the antibody response to COVID-19 BNT162b2 / Comirnaty vaccine is only reached after the second dose, across all adult age ranges
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.19.21253680
DO 10.1101/2021.03.19.21253680
A1 Viana, João F.
A1 Bergman, Marie-Louise
A1 Gonçalves, Lígia A.
A1 Duarte, Nádia
A1 Coutinho, Teresa Penha
A1 Borges, Patrícia C.
A1 Diwo, Christian
A1 Castro, Rute
A1 Matoso, Paula
A1 Malheiro, Vanessa
A1 Brennand, Ana
A1 Kosack, Lindsay
A1 Akpogheneta, Onome
A1 Figueira, João M.
A1 Cardoso, Conceição
A1 Casaca, Ana M.
A1 Alves, Paula M.
A1 Nunes, Telmo
A1 Penha-Gonçalves, Carlos
A1 Demengeot, Jocelyne
YR 2021
UL http://medrxiv.org/content/early/2021/06/04/2021.03.19.21253680.abstract
AB BACKGROUND While mRNA vaccines authorized for emergency use are administrated worldwide in an effort to contain the COVID-19 pandemic, little is known about the heterogeneity of the humoral immune response they induce at the population scale.METHODS We conducted a prospective observational longitudinal study in 1245 hospital care workers and 146 nursing home residents, together covering adult ages from 19 to 99 years. Blood samples were taken before vaccination, 3-5 weeks after the first vaccine dose, and 3 weeks after the second dose of BNT162b2 mRNA COVID-19 (Comirnaty, Pfizer/BioNTech). End points were seroconversion to SARS-CoV-2 spike protein and amount of spike-specific IgG, IgM and IgA following the first dose and the boosting effect of the second vaccination. We also addressed the effect of age, sex and pre-exposure to SARSCov-2 on these parameters.RESULTS Among 1067 baseline seronegative participants, seroconversion after the first vaccine dose varied from a maximum of 98,6% in the younger age strata [19-29 years] to a minimum of 25.4 % in the older age group [70-100 years], while sex had little effect. Large inter-individual variation in the amplitude of the antibody response were observed in all age strata. The second dose brought seroconversion to high frequency (100% and 94.9% in younger and older age strata, respectively) and homogenised IgG responses to high levels, while IgM and IgA levels remained low and heterogeneous. Previous exposure to SARS-Cov-2 boosted IgG level after a single injection. Seven non-responders were identified after the second dose.CONCLUSIONS In this large study, covering all adult age ranges, BNT162b2 vaccination resulted in isotypic and heterogeneous antibody responses, advocating for the interval between the two doses not to be extended and for serological monitoring of elderly and immunosuppressed vaccinees.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work benefited from COVID19 emergency funds 2020 from Fundacao Gulbenkian de Ciencia, Camara Municipal de Oeiras, and Camara Municipal de Almeirim.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Ethics committees of the Centro Hospitalar Lisboa Ocidental and the Administracao Regional de Lisboa e Vale do Tejo, in compliance with the Declaration of Helsinki, and follows international and national guidelines for health data protection.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAnonymised raw data for Ig levels will be made available on demand. Biometric data will not be shared.